STOCK TITAN
  1. Home
  2. Sec-filings
  3. DXCM
  4. [Form 4] DEXCOM INC Insider Trading Activity

DexCom (NASDAQ: DXCM) director receives 5,605 RSUs equity grant

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Driscoll Rimma reported acquisition or exercise transactions in this Form 4 filing.

DexCom Inc. director Rimma Driscoll received a compensation-related stock award. She was granted 5,605 shares of DexCom common stock in the form of restricted stock units at a price of $0.00 per share.

The RSU award was granted on May 28, 2026 and will vest 100% on the earlier of the one-year anniversary of the grant date or the date of DexCom’s 2027 Annual Meeting of Stockholders. Each restricted stock unit represents a contingent right to receive one DexCom common share upon settlement.

After this award, Driscoll directly holds 17,319 DexCom shares, which include 6,941 unvested restricted stock units. Of these unvested units, 5,605 were granted on May 28, 2026 and 1,336 were granted on August 24, 2023, scheduled to vest through August 24, 2026.

Positive

  • None.

Negative

  • None.
Insider Driscoll Rimma
Role null
Type Security Shares Price Value
Grant/Award Common Stock 5,605 $0.00 --
Holdings After Transaction: Common Stock — 17,319 shares (Direct, null)
Footnotes (1)
  1. The RSU Award was granted on May 28, 2026 and 100% of the RSU Award will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement. Included in this number are 6,941 unvested restricted stock units, 5,605 of which were granted on May 28, 2026 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders, and 1,336 of which were granted on August 24, 2023 and shall vest through August 24, 2026.
RSU grant size 5,605 shares Restricted stock units granted May 28, 2026
Grant price per share $0.00 per share RSU award to director Rimma Driscoll
Total shares after transaction 17,319 shares Direct holdings following RSU grant
Total unvested RSUs 6,941 units Unvested restricted stock units included in holdings
New 2026 unvested RSUs 5,605 units Granted May 28, 2026; vest by 2027 meeting or one-year anniversary
2023 RSU grant balance 1,336 units Granted August 24, 2023; vest through August 24, 2026
restricted stock unit financial
"Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
contingent right financial
"represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement"
Annual Meeting of Stockholders financial
"will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders"
vest financial
"will vest on the earlier of the one year anniversary of the grant date or the date"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Driscoll Rimma
(Last)(First)(Middle)
6340 SEQUENCE DRIVE
(Street)
SAN DIEGO CALIFORNIA 92121
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
DEXCOM INC [ DXCM ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/28/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/28/2026A5,605(1)A$017,319(2)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The RSU Award was granted on May 28, 2026 and 100% of the RSU Award will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement.
2. Included in this number are 6,941 unvested restricted stock units, 5,605 of which were granted on May 28, 2026 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders, and 1,336 of which were granted on August 24, 2023 and shall vest through August 24, 2026.
Remarks:
Exhibit 24 - Power of Attorney
/s/ Jereme M. Sylvain, as Attorney-in-Fact for Rimma Driscoll06/01/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did DexCom (DXCM) report for Rimma Driscoll?

DexCom reported that director Rimma Driscoll received a grant of 5,605 restricted stock units of DexCom common stock on May 28, 2026, as a compensation-related award at a price of $0.00 per share.

How many DexCom (DXCM) shares does Rimma Driscoll hold after this Form 4?

After the reported grant, Rimma Driscoll directly holds 17,319 DexCom shares. This total includes 6,941 unvested restricted stock units made up of the new 2026 award and an earlier 2023 RSU grant.

What are the vesting terms of Rimma Driscoll’s new DexCom (DXCM) RSU grant?

The 5,605 new RSUs granted to Rimma Driscoll on May 28, 2026 will vest 100% on the earlier of the one-year anniversary of the grant date or the date of DexCom’s 2027 Annual Meeting of Stockholders.

How many unvested DexCom (DXCM) RSUs from prior grants does Rimma Driscoll hold?

Rimma Driscoll’s total 6,941 unvested RSUs include 1,336 restricted stock units granted on August 24, 2023, which are scheduled to vest in installments through August 24, 2026, alongside the new 2026 award.

Does Rimma Driscoll’s DexCom (DXCM) Form 4 reflect a market purchase or sale?

The Form 4 reflects an RSU grant, not an open-market trade. It shows a grant/award acquisition of 5,605 restricted stock units at $0.00 per share, typical of equity-based director compensation rather than a buy or sell in the market.

What does each DexCom (DXCM) restricted stock unit in this grant represent?

Each restricted stock unit in this award represents a contingent right to receive one share of DexCom common stock upon settlement, subject to the vesting schedule tied to the one-year anniversary or the 2027 Annual Meeting of Stockholders.